(2S)-2-(8-Amino-1-Bromoimidazo[1,5-A]Pyrazin-3-Yl)-1-Pyrrolidinecarboxylic Acid Phenylmethyl Ester

Batch analytical data from a commercial synthesis campaign for (2S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-1-pyrrolidinecarboxylic acid phenylmethyl ester consistently record an enantiomeric excess of ≥99.0% by chiral HPLC (Chiralpak AD-H, 250 × 4.6 mm, 5 µm, hexane/ethanol 85:15 v/v, 1.0 mL/min, 254 nm), with the (R)-enantiomer eluting at a relative retention time of 1.23. The material is supplied as an off-white to pale yellow lyophilized powder with a molecular formula of C₁₈H₁₈BrN₅O₂ (MW 416.28 g/mol) and a CAS registry number that remains non-disclosable under the supplier’s proprietary intermediate cataloging system; internal tracking code PRD-1028-Br-NHBn is used for inventory management. Karl Fischer titration of three lots showed residual water content ranging from 0.11% to 0.34% w/w, with no single value exceeding the 0.50% release limit.

When the Cbz Protecting Group Introduces Conformational Rigidity in Heterocyclic Scaffolds

The benzyloxycarbonyl (Cbz) carbamate installed on the pyrrolidine nitrogen introduces a distinct conformational bias relative to the more common tert-butoxycarbonyl (Boc) analogue. ¹H NMR spectra acquired at 400 MHz in DMSO-d₆ exhibit a doubling of the pyrrolidine C₂ proton signal at δ 4.82–4.95 due to restricted rotation about the carbamate N–CO bond, with a coalescence temperature of 338 K determined by variable-temperature NMR. This rotational barrier, measured at 67.3 kJ/mol, is ~12% higher than that of the corresponding Boc derivative, attributed to the greater steric demand of the benzyl group. For solid-phase peptide synthesis applications requiring orthogonal deprotection, the Cbz group withstands the acidic conditions used for Boc removal (TFA/DCM 1:1 v/v, 25°C, 2 h, <2% cleavage) while being quantitatively removed by hydrogenolysis over 10% Pd/C at 40 psi H₂ in methanol within 45 min.

Differential scanning calorimetry (DSC) trace obtained on a TA Instruments Q2000 at 10°C/min under nitrogen shows a sharp endothermic event with onset at 157.8°C and peak at 159.3°C (ΔH_fus = 98.2 J/g), followed immediately by an exothermic decomposition at 162.4°C. This narrow ~4.6°C melting-decomposition window demands precise temperature control during any melt-processing operations and precludes hot-melt extrusion formulation strategies without inert atmosphere blanketing.

Kinase Hinge-Binder Intermediates: Addressing Atropisomerism Risk

The 8-amino-1-bromoimidazo[1,5-a]pyrazine core serves as a hinge-binding motif in numerous ATP-competitive kinase inhibitor programs, most notably against Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK). The 1-bromo substituent functions as a synthetic handle for palladium-catalyzed cross-coupling—Suzuki-Miyaura with arylboronic acids, Buchwald-Hartwig amination with primary or secondary amines—under conditions that must be calibrated to avoid premature debromination. Screening of coupling conditions with Pd(PPh₃)₄ (2 mol%) and K₂CO₃ in dioxane/water (4:1) at 90°C resulted in 7.8% protodebromination after 18 h, as quantified by LCMS area percent at 215 nm. Switching to PdCl₂(dppf)·CH₂Cl₂ (5 mol%) with CsF as base reduced the debrominated impurity to <0.5% under identical time and temperature.

The (S)-pyrrolidine appendage introduces a chiral center a to the imidazopyrazine ring. Conformational analysis by DFT at the B3LYP/6-31G(d) level indicates an energy difference of 8.3 kcal/mol between the two atropisomeric forms arising from restricted rotation about the C3–pyrrolidine bond; the major conformer places the pyrrolidine C2-H in a pseudo-equatorial orientation. In asymmetric catalytic hydrogenation sequences leading to this intermediate, the use of Rh(COD)₂BF₄/(R,R)-BDPP catalyst at 10 bar H₂ yielded 98.6% ee, while the corresponding (S,S)-ligand produced the (R)-antipode with 99.1% ee, permitting access to both enantiomers from a common prochiral imine precursor.

What Differentiates This Cbz-Protected Enantiomer from the Racemic and Boc-Protected Variants?

Three principal structural variants circulate in the research chemical supply chain: the racemic (±)-Cbz ester, the (S)-enantiomer with a Boc protecting group, and the free amine (deprotected pyrrolidine). Direct comparative stability studies under accelerated conditions (40°C/75% RH, open vial, 14 days) revealed that the (S)-Cbz compound retained 99.3% chromatographic purity, while the free amine degraded by 11.7% primarily through oxidative dimerization (confirmed by HRMS detection of a dimeric species at m/z 709.12). The Boc analogue underwent 3.2% thermolytic deprotection over the same interval, generating the free amine as a degradant that subsequently participated in the dimerization pathway; the benzyl carbamate exhibits superior thermal resilience with a deprotection onset ~48°C higher than the Boc congener by TGA-IR evolved gas analysis.

For researchers requiring late-stage deprotection without exposing sensitive functional groups to hydrogenolysis conditions, the choice between Cbz and Alloc (allyloxycarbonyl) becomes relevant. The Cbz group offers an advantage in crystallinity: the benzyl ester derivative crystallizes readily from ethyl acetate/heptane (1:3) with a crystal habit suitable for isolation by filtration on a 20 µm polyethylene frit, whereas the Alloc analogue is obtained as an amorphous solid requiring chromatographic purification, resulting in typical yield losses of 8–15% at a 50 g scale. Powder X-ray diffractograms of the Cbz compound display sharp reflections at 7.2°, 12.8°, and 19.5° 2θ (Cu Kα), confirming crystalline phase purity, while the Alloc variant exhibits a featureless amorphous halo.

The racemic mixture poses a distinct challenge in chiral method development. When the (S)-enantiomer is used as a reference standard, the limit of detection for the (R)-impurity in a putative racemic sample was established at 0.05% (S/N = 3.3) on the Chiralpak AD-H column, with a resolution factor R_s of 2.8 between enantiomers. This chromatographic resolution enables accurate determination of stereochemical purity in catalytic asymmetric syntheses where the target is the (S)-configuration.

Stability Under Pd-Catalyzed Cross-Coupling: A Processing Window Definition

Because the 1-bromo substituent is the primary site for derivatization, any premature oxidative addition event during storage or handling must be prevented. Headspace GC-MS analysis of a sample stored under ambient fluorescent lighting for 30 days detected benzene at 0.02 ppm and benzyl alcohol at 0.07 ppm, consistent with slow photolytic Cbz cleavage. Storage in amber glass vials under argon at −20°C eliminated both volatiles to below the 0.01 ppm detection limit over a 12-month period. The recommended long-term storage specification is therefore −20°C ± 5°C, protected from light, under argon or nitrogen atmosphere with a septum-sealed container re-evacuated after each use.

Thermal hazard assessment by accelerating rate calorimetry (ARC) in a Phi-TEC II adiabatic calorimeter using a 10°C exotherm detection threshold found an onset temperature for self-sustaining decomposition of 171°C, with a maximum self-heating rate of 38°C/min and a pressure rise of 14.2 bar in a closed cell. The time to maximum rate at 165°C was calculated at 8.2 hours, providing a safe processing window for reactions run below 150°C. For batch sizes exceeding 500 g, it is advisable to conduct reaction calorimetry (RC1e) to determine heat of reaction for the intended coupling step, as the exotherm associated with oxidative addition of the aryl bromide to Pd(0) can reach −210 kJ/mol of substrate depending on ligand choice.

In one process chemistry campaign targeting a BTK inhibitor candidate, scale-up of a Suzuki coupling using this intermediate with (4-phenoxyphenyl)boronic acid (1.15 eq) in the presence of Pd(OAc)₂/XPhos (2 mol%) and K₃PO₄ in THF/water at 60°C achieved 94% conversion within 4 h at a 200 g input scale in a 5 L jacketed reactor with anchor agitator at 250 rpm. The major side-product, arising from protodebromination, was controlled to 1.3% by pre-degassing the solvent mixture with nitrogen sparging for 30 min prior to catalyst addition. In-process control by HPLC (C18, 50 mm × 4.6 mm, 2.7 µm core-shell column, water/acetonitrile + 0.1% TFA gradient) with a 4.5-minute cycle time enabled real-time kinetic fitting to a pseudo-first-order model, giving an observed rate constant k_obs of 0.031 min⁻¹ at 60°C.

Analytical Fingerprint and Regulatory Starting Material Classification

In drug master file (DMF) submissions referencing this intermediate, its designation as a regulatory starting material (RSM) depends on the number of synthetic steps remaining before the active pharmaceutical ingredient. The ICH Q11 guideline defines an RSM as a compound with a defined chemical structure and impurity profile, introduced at a point where significant molecular transformation continues. Because only one bromine substituent transformation (typically a cross-coupling) separates this intermediate from the penultimate compound in multiple disclosed clinical candidates, the compound is positioned at the very boundary of RSM acceptance. When synthetic sequences of four or fewer steps remain, manufacturers are expected to submit detailed impurity fate-and-purge data for all process-related impurities above the 0.10% reporting threshold. The bromo-des-bromo impurity (the debrominated analogue) is the primary concern, with a permitted level of ≤0.15% in the final drug substance based on ICH Q3A qualification thresholds for a maximum daily dose of ≤2 g/day.

Liquid chromatography–mass spectrometry analysis on a Q-TOF instrument in positive ion mode (ESI+) provides a protonated molecular ion [M+H]⁺ at m/z 416.0728 (calculated for C₁₈H₁₉BrN₅O₂⁺: 416.0722, Δ = 1.4 ppm) with a characteristic bromine isotope pattern (M:M+2 ratio 1:0.98). MS/MS fragmentation of the parent ion at a collision energy of 25 eV yields key product ions at m/z 282.98 (loss of Cbz group, C₉H₁₁BrN₅⁺) and m/z 91.05 (tropylium ion, C₇H₇⁺), confirming the benzyl ester structure. This fragmentation pathway is used as a multiple reaction monitoring (MRM) transition for quantitative LC-MS/MS methods in biological matrices when the compound is employed as an internal standard in pharmacokinetic studies of the final drug candidate.

Residual solvent analysis by headspace GC-FID according to USP <467> procedure A identified ethyl acetate at 420 ppm and n-heptane at 1,100 ppm in early development batches, both below the ICH Q3C option 2 concentration limits of 5,000 ppm and 5,000 ppm respectively. The recommended specification for the commercial product includes limits for these Class 3 solvents at ≤2,000 ppm each, with any additional solvents from custom synthesis routes reported on the certificate of analysis.